A Successful Exit for eNicotine
In August 2015, LSA’s portfolio company eNicotine was successfully sold, yielding a positive return for its investors. The purchasing company, one of the world’s largest tobacco and e-cigarette producers, intends to utilize eNicotine’s technology within its product line of future e-cigarettes. The technology will first be released in Europe, and is being prepared for release in a relatively short period of time.
Tiatros named Global Digital Health 100 company
In February 2015, Tiatros, an LSA portfolio company, was added to the Global Digital Health 100 Award list, which recognizes the most innovative companies working in the mobile and digital health sectors today. Reflecting the evolving importance of mobile technologies and digital solutions within the healthcare sector, the list acknowledge the significant work being carried out, in this field, by pioneering organizations from around the globe.
Life Science Angels Ranked Top Angel Group in the U.S.
In August 2014, Life Science Angels was named the Top Angel Investment Group in the U.S. LSA was recognized by CB Insights as the best performer out of 370 angel groups analyzed nationwide based on criteria that included: historical performance, network strength (connections), selection aptitude and brand recognition.
Nanostim Receives Prestigious Innovation Award
In June 2014, Nanostim, a Life Science Angels portfolio company that offers a leadless pacemaker was awarded the 2014 Innovation Award at Cardiostim 2014, the 19th World Congress in Cardiac Electrophysiology and Cardiac Techniques.
Gemmus Pharma Closes $3.3M Series B Funding
In May 2014, LSA’s portfolio company Gemmus Pharma (dedicated developing improved host-targeted treatment for the flu called SuperiorFlu) closed its Series B funding round, raising $3.3M from a syndicate of angel groups led by the Life Science Angels (LSA) and including BlueTree Allied Angels, The Angels’ Forum, Tech Coast Angels and Wilmington Investor Network, and a collection of individual investors.